Pfizer reports positive results in study of vaccine for immunocompromised adults at risk of severe RSV-related illness

Pfizer plans to share the findings at a scientific conference and publish them in a peer-reviewed scientific journal. The company will also submit the data to regulatory agencies for review.

Previous post Leveraged funds roll back bets against yen by widest margin in years as carry trade unwinds
Next post Venezuela restricts access to Binance and X amid election unrest